[1]
|
Mocarzel, L.O., Bicca, J., Jarske, L., et al. (2016) Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome. Case Reports in Gastroenterology, 10, 531-537.
https://doi.org/10.1159/000448885
|
[2]
|
Basili, S., Pastori, D., Raparelli, V., et al. (2018) Anticoagulant Therapy in Patients with Liver Cirrhosis and Portal Vein Thrombosis: Insights for the Clinician. Therapeutic Advances in Gastroen-terology, 11, 1756284818793561.
https://doi.org/10.1177/1756284818793561
|
[3]
|
Gîrleanu, I., Trifan, A., Stanciu, C., et al. (2018) Portal Vein Thrombosis in Cirrhotic Patients—It Is Always the Small Pieces that Make the Big Picture. World Journal of Gastroen-terology, 24, 4419-4427.
https://doi.org/10.3748/wjg.v24.i39.4419
|
[4]
|
Lankarani, K.B., Homayon, K., Motevalli, D., et al. (2015) Risk Factors for Portal Vein Thrombosis in Patients With Cirrhosis Awaiting Liver Transplantation in Shiraz, Iran. Hepatitis Monthly, 15, e26407.
https://doi.org/10.5812/hepatmon.26407
|
[5]
|
Zafar, M., Heslop-Harrison, W., Loterh, L., et al. (2022) Splenic Vein Thrombosis: A Case Series of Consequential Chronic Pancreatitis and Sequential Myeloproliferative Disorder. Cu-reus, 14, e25924.
https://doi.org/10.7759/cureus.25924
|
[6]
|
Xian, J., Tang, Y., Shao, H., et al. (2021) Effect of Portal Vein Throm-bosis on the Prognosis of Patients with Cirrhosis without a Liver Transplant: A Systematic Review and Meta-Analysis. Medicine, 100, e25439.
https://doi.org/10.1097/MD.0000000000025439
|
[7]
|
Senzolo, M., Piano, S., Shalaby, S., et al. (2021) Compari-son of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. The American Journal of Medicine, 134, 1278-1285.
https://doi.org/10.1016/j.amjmed.2021.05.013
|
[8]
|
EASL (2016) EASL Clinical Practice Guidelines: Vascular Diseases of the Liver. Journal of Hepatology, 64, 179-202.
https://doi.org/10.1016/j.jhep.2015.07.040
|
[9]
|
Northup, P.G., Garcia-Pagan, J.C., Garcia-Tsao, G., et al. (2021) Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients with Liver Disease: 2020 Prac-tice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 73, 366-413. https://doi.org/10.1002/hep.31646
|
[10]
|
Beyer-Westendorf, J. and Marten, S. (2021) Reproductive Issues in Women on Direct Oral Anticoagulants. Research and Practice in Thrombosis and Haemostasis, 5, e12512. https://doi.org/10.1002/rth2.12512
|
[11]
|
Marcucci, M., Etxeandia-Ikobaltzeta, I., Yang, S., et al. (2022) Benefits and Harms of Direct Oral Anticoagulation and Low Molecular Weight Heparin for Thromboprophylaxis in Patients Under-going Non-Cardiac Surgery: Systematic Review and Network Meta-Analysis of Randomised Trials. BMJ, 376, e066785.
https://doi.org/10.1136/bmj-2021-066785
|
[12]
|
Anderson, D.R., Morgano, G.P, Bennett, C., et al. (2019) American Society of Hematology 2019 Guidelines for Management of Venous Thromboembolism: Prevention of Venous Throm-boembolism in Surgical Hospitalized Patients. Blood Advances, 3, 3898-3944. https://doi.org/10.1182/bloodadvances.2019000975
|
[13]
|
Imberti, D., Pomero, F. and Mastroiacovo, D. (2020) Di-rect Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: Insights from the EINSTEIN CHOICE Study. Blood Transfusion, 18, 49-57.
|
[14]
|
De Franchis, R., Bosch, J., Garcia-Tsao, G., et al. (2022) Baveno VII-Renewing Consensus in Portal Hypertension. Journal of Hepatology, 76, 959-974. https://doi.org/10.1016/j.jhep.2021.12.022
|
[15]
|
O’Leary, J.G., Greenberg, C.S., Patton, H.M., et al. (2019) AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology, 157, 34-43.E1. https://doi.org/10.1053/j.gastro.2019.03.070
|
[16]
|
Ponziani, F.R., De Stefano, V. and Gasbarrini, A. (2009) Viral Cirrhosis: An Overview of Haemostatic Alterations and Clinical Consequences. Mediterranean Journal of Hematology and Infectious Diseases, 1, e2009033.
https://doi.org/10.4084/MJHID.2009.033
|
[17]
|
Mcconnell, M.J., Kondo, R., Kawaguchi, N., et al. (2022) Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. Hepatology Communi-cations, 6, 255-269.
https://doi.org/10.1002/hep4.1843
|
[18]
|
Xu, S., Guo, X., Yang, B., et al. (2021) Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. Clinical and Translational Gastroenterology, 12, e00409.
https://doi.org/10.14309/ctg.0000000000000409
|
[19]
|
Leonardi, F., Maria, N.D. and Villa, E. (2017) Anticoagula-tion in Cirrhosis: A New Paradigm? Clinical and Molecular Hepatology, 23, 13-21. https://doi.org/10.3350/cmh.2016.0110
|
[20]
|
Wang, L., Guo, X., Xu, X., et al. (2021) Anticoagulation Favors Thrombus Recanalization and Survival in Patients with Liver Cirrhosis and Portal Vein Thrombosis: Results of a Me-ta-Analysis. Advances in Therapy, 38, 495-520.
https://doi.org/10.1007/s12325-020-01550-4
|
[21]
|
Llop, E. and Seijo, S. (2016) Treatment of Non-Cirrhotic, Non-Tumoural Portal Vein Thrombosis. Gastroenterology & Hepatology, 39, 403-410. https://doi.org/10.1016/j.gastrohep.2015.09.007
|
[22]
|
Deleve, L.D., Valla, D.C. and Garcia-Tsao, G. (2009) Vascu-lar Disorders of the Liver. Hepatology, 49, 1729-1764.
https://doi.org/10.1002/hep.22772
|
[23]
|
Simonetto, D.A., Singal, A.K., Garcia-Tsao, G., et al. (2020) ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. The American Journal of Gastroenterology, 115, 18-40.
https://doi.org/10.14309/ajg.0000000000000486
|
[24]
|
Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology and Chinese Medical Association (2020) Consensus for Management of Portal Vein Thrombosis in Liver Cirrhosis (2020, Shanghai). Journal of Digestive Diseases, 22, 176-186.
|
[25]
|
Priyanka, P., Kupec, J.T., Krafft, M., et al. (2018) Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. International Journal of Hepatology, 2018, Article ID: 8432781.
https://doi.org/10.1155/2018/8432781
|
[26]
|
Steffel, J., Verhamme, P., Potpara, T.S., et al. (2018) The 2018 Euro-pean Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. European Heart Journal, 39, 1330-1393. https://doi.org/10.1093/eurheartj/ehy136
|
[27]
|
Konstantinides, S.V., Meyer, G., Becattini, C., et al. (2019) 2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaborate on with the European Respiratory Society (ERS): The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). European Respiratory Journal, 54, Article 1901647. https://doi.org/10.1183/13993003.01647-2019
|
[28]
|
Agnelli, G., Buller, H.R., Cohen, A., et al. (2013) Oral Apixa-ban for the Treatment of Acute Venous Thromboembolism. The New England Journal of Medicine, 369, 799-808. https://doi.org/10.1056/NEJMoa1302507
|
[29]
|
Schulman, S., Kakkar, A.K., Goldhaber, S.Z., et al. (2014) Treat-ment of Acute Venous Thromboembolism with Dabigatran or Warfarin and Pooled Analysis. Circulation, 129, 764-772.
https://doi.org/10.1161/CIRCULATIONAHA.113.004450
|
[30]
|
Hokusai, V.T.E.I., Buller, H.R., Decousus, H., et al. (2013) Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. The New England Journal of Medicine, 369, 1406-1415.
https://doi.org/10.1056/NEJMoa1306638
|
[31]
|
Ng, C.H., Tan, D.J.H., Nistala, K.R.Y., et al. (2021) A Network Meta-Analysis of Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis. Hepatology International, 15, 1196-1206.
https://doi.org/10.1007/s12072-021-10247-x
|
[32]
|
Mohan, B.P., Aravamudan, V.M., Khan, S.R., et al. (2020) Treatment Response and Bleeding Events Associated with Anticoagulant Therapy of Portal Vein Thrombosis in Cirrhotic Patients: Systematic Review and Meta-Analysis. Annals of Gastroenterology, 33, 521-527. https://doi.org/10.20524/aog.2020.0503
|
[33]
|
Davis, k.A., Joseph, J. and Nisly, S.A. (2020) Direct Oral Anticoag-ulants and Warfarin in Patients with Cirrhosis: A Comparison of Outcomes. Journal of Thrombosis and Thrombolysis, 50, 457-461.
https://doi.org/10.1007/s11239-019-02035-0
|
[34]
|
Ghazaleh, S., Beran, A., Aburayyan, K., et al. (2021) Efficacy and Safety of Anticoagulation in Non-Malignant Portal Vein Thrombosis in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis. Annals of Gastroenterology, 34, 104-110. https://doi.org/10.20524/aog.2020.0544
|
[35]
|
Salerno, D.M., Tsapepas, D., Papachristos, A., et al. (2017) Direct Oral Anticoagulant Considerations in Solid Organ Transplantation: A Review. Clinical Transplantation, 31, e12873. https://doi.org/10.1111/ctr.12873
|
[36]
|
Kubitza, D., Roth, A., Becka, M., et al. (2013) Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of a Single Dose of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor. British Journal of Clinical Pharmacology, 76, 89-98. https://doi.org/10.1111/bcp.12054
|
[37]
|
Graff, J. and Harder, S. (2013) Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment. Clinical Pharmacokinetics, 52, 243-254. https://doi.org/10.1007/s40262-013-0034-0
|
[38]
|
Violi, F., Loffredo, L. and Pastori, D. (2021) Anticoagulation in Patients with Advanced Liver Disease: An Open Issue. Internal and Emergency Medicine, 16, 61-71. https://doi.org/10.1007/s11739-020-02526-6
|
[39]
|
Harder, S. (2014) Pharmacokinetic and Pharmacodynamic Eval-uation of Rivaroxaban: Considerations for the Treatment of Venous Thromboembolism. Thrombosis Journal, 12, Article No. 22. https://doi.org/10.1186/1477-9560-12-22
|
[40]
|
Ufer, M. (2010) Comparative Efficacy and Safety of the Novel Oral Anticoagulants Dabigatran, Rivaroxaban and Apixaban in Preclinical and Clinical Development. Thrombosis and Haemostasis, 103, 572-585.
https://doi.org/10.1160/TH09-09-0659
|
[41]
|
Kvasnicka, T., Malikova, I., Zenahlikova, Z., et al. (2017) Rivaroxa-ban-Metabolism, Pharmacologic Properties and Drug Interactions. Current Drug Metabolism, 18, 636-642. https://doi.org/10.2174/1389200218666170518165443
|
[42]
|
Willmann, S., Zhang, L., Frede, M., et al. (2018) Inte-grated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations. CPT: Pharmacomet-rics & Systems Pharmacology, 7, 309-320.
https://doi.org/10.2174/1389200218666170518165443
|
[43]
|
Lv, Y., Bai, W., Li, K., et al. (2021) Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Pro-spective Observational Study. The American Journal of Gastroenterology, 116, 1447-1464. https://doi.org/10.14309/ajg.0000000000001194
|
[44]
|
Hanafy, A.S., Abd-Elsalam, S. and Dawoud, M.M. (2019) Randomized Controlled Trial of Rivaroxaban versus Warfarin in the Management of Acute Non-Neoplastic Portal Vein Thrombosis. Vascular Pharmacology, 113, 86-91.
https://doi.org/10.1016/j.vph.2018.05.002
|
[45]
|
Raymond, J., Imbert, L., Cousin, T., et al. (2021) Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. Journal of Personalized Medicine, 11, Article 37. https://doi.org/10.3390/jpm11010037
|
[46]
|
Kanuri, S.H. and Kreutz, R.P. (2019) Pharmacogenomics of Novel Di-rect Oral Anticoagulants: Newly Identified Genes and Genetic Variants. Journal of Personalized Medicine, 9, Article 7. https://doi.org/10.3390/jpm9010007
|
[47]
|
Gomez-Outes, A., Suarez-Gea, M.L., Lecumberri, R., et al. (2013) Po-tential Role of New Anticoagulants for Prevention and Treatment of Venous Thromboembolism in Cancer Patientsz. Vascular Health and Risk Management, 9, 207-228. https://doi.org/10.2147/VHRM.S35843
|
[48]
|
Aryal, M.R., Gosain, R., Donato, A., et al. (2019) Systematic Review and Meta-Analysis of the Efficacy and Safety of Apixaban Compared to Rivaroxaban in Acute VTE in the Real World. Blood Advances, 3, 2381-2387.
https://doi.org/10.1182/bloodadvances.2019000572
|
[49]
|
Mookadam, M., Shamoun, F.E., Ramakrishna, H., et al. (2015) Perioperative Venous Thromboembolic Disease and the Emerging Role of the Novel Oral Anticoagulants: An Analysis of the Implications for Perioperative Management. Annals of Cardiac Anaesthesia, 18, 517-527. https://doi.org/10.4103/0971-9784.166461
|
[50]
|
Pruszczyk, P., Tomaszuk-Kazberuk, A., Slowik, A., et al. (2017) Management of Bleeding or Urgent Interventions in Patients Treated with Direct Oral Anticoagulants: 2017 Recommen-dations for Poland. Polish Archives of Internal Medicine, 127, 343-351. https://doi.org/10.20452/pamw.3995
|
[51]
|
Nagaoki, Y., Aikata, H., Daijyo, K., et al. (2018) Efficacy and Safety of Edoxaban for Treatment of Portal Vein Thrombosis Following Danaparoid Sodium in Patients with Liver Cirrhosis. Hepatology Research, 48, 51-58.
https://doi.org/10.1111/hepr.12895
|
[52]
|
Blech, S., Ebner, T., Ludwig-Schwellinger, E., et al. (2008) The Metabo-lism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans. Drug Metabolism & Disposition, 36, 386-399.
https://doi.org/10.1124/dmd.107.019083
|
[53]
|
Burstein, B., Wieruszewski, P.M., Zhao, Y.J., et al. (2019) Antico-agulation with Direct Thrombin Inhibitors during Extracorporeal Membrane Oxygenation. World Journal of Critical Care Medicine, 8, 87-98.
https://doi.org/10.5492/wjccm.v8.i6.87
|
[54]
|
Naymagon, L., Tremblay, D., Zubizarreta, N., et al. (2020) The Effi-cacy and Safety of Direct Oral Anticoagulants in Noncirrhotic Portal Vein Thrombosis. Blood Advances, 4, 655-666.
https://doi.org/10.1182/bloodadvances.2019001310
|
[55]
|
Potze, W., Adelmeijer, J. and Lisman, T. (2015) De-creased in Vitro Anticoagulant Potency of Rivaroxaban and Apixaban in Plasma from Patients with Cirrhosis. Hepatolo-gy, 61, 1435-1436. https://doi.org/10.1002/hep.27350
|